Profile data is unavailable for this security.
About the company
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
- Revenue in USD (TTM)118.31m
- Net income in USD96.34m
- Incorporated1987
- Employees58.00
- LocationLigand Pharmaceuticals Inc555 Heritage Drive, Suite 200JUPITER 33458United StatesUSA
- Phone+1 (858) 550-7500
- Fax+1 (302) 636-5454
- Websitehttps://www.ligand.com/
Mergers & acquisitions
Acquired company | LGND:NMQ since announced | Transaction value |
---|---|---|
Novan Inc | 25.35% | 12.20m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Soleno Therapeutics Inc | 0.00 | -52.03m | 1.46bn | 33.00 | -- | 9.78 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
Xencor Inc | 162.18m | -133.36m | 1.47bn | 280.00 | -- | 2.39 | -- | 9.03 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Tilray Brands Inc | 743.25m | -351.95m | 1.49bn | 1.60k | -- | 0.4148 | -- | 2.00 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.121 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.49bn | 20.00 | -- | 15.12 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Supernus Pharmaceuticals Inc | 597.40m | -15.51m | 1.49bn | 652.00 | -- | 1.60 | 21.44 | 2.50 | -0.2843 | -0.2843 | 10.86 | 16.90 | 0.3859 | 0.922 | 4.10 | 916,259.20 | -1.00 | 4.95 | -1.51 | 6.41 | 87.17 | 88.61 | -2.60 | 12.84 | 1.49 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
Morphic Holding Inc | 0.00 | -161.25m | 1.52bn | 124.00 | -- | 2.29 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.52bn | 284.00 | -- | -- | -- | 36.64 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.53bn | 58.00 | 16.25 | 1.89 | 11.56 | 12.91 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.53bn | 154.00 | -- | 19.55 | -- | 27.80 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
Dynavax Technologies Corp | 236.15m | 9.22m | 1.57bn | 408.00 | 240.04 | 2.54 | 114.76 | 6.65 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Kura Oncology Inc | 0.00 | -168.09m | 1.57bn | 142.00 | -- | 3.11 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
Neumora Therapeutics Inc | 0.00 | -254.02m | 1.58bn | 120.00 | -- | 3.72 | -- | -- | -2.44 | -2.44 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 1.59bn | 111.00 | -- | 3.71 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.60bn | 92.00 | -- | 2.99 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Ardelyx Inc | 159.11m | -65.81m | 1.61bn | 267.00 | -- | 10.64 | -- | 10.09 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Taro Pharmaceutical Industries Ltd | 629.18m | 53.87m | 1.61bn | 1.55k | 29.88 | 0.8977 | 18.94 | 2.56 | 1.43 | 1.43 | 16.74 | 47.70 | 0.2928 | 1.50 | 3.31 | -- | 2.51 | -0.166 | 3.03 | -0.2023 | 48.47 | 52.85 | 8.56 | -0.6294 | 3.04 | -- | 0.00 | -- | 9.81 | -1.25 | 111.70 | -28.17 | 12.06 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.63m | 14.85% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.85m | 10.47% |
Macquarie Investment Management Business Trustas of 31 Mar 2024 | 1.03m | 5.84% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.00m | 5.65% |
Stephens Investment Management Group LLCas of 31 Mar 2024 | 697.85k | 3.94% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 671.28k | 3.79% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 664.08k | 3.75% |
Cardinal Capital Management LLCas of 31 Mar 2024 | 559.24k | 3.16% |
St. Denis J. Villere & Co. LLCas of 31 Mar 2024 | 490.75k | 2.77% |
Geode Capital Management LLCas of 31 Mar 2024 | 380.97k | 2.15% |